Literature DB >> 18664580

mTORC1 promotes survival through translational control of Mcl-1.

John R Mills1, Yoshitaka Hippo, Francis Robert, Samuel M H Chen, Abba Malina, Chen-Ju Lin, Ulrike Trojahn, Hans-Guido Wendel, Al Charest, Roderick T Bronson, Scott C Kogan, Robert Nadon, David E Housman, Scott W Lowe, Jerry Pelletier.   

Abstract

Activation of the phosphatidylinositol 3-kinase (PI3K)/AKT signaling pathway is a frequent occurrence in human cancers and a major promoter of chemotherapeutic resistance. Inhibition of one downstream target in this pathway, mTORC1, has shown potential to improve chemosensitivity. However, the mechanisms and genetic modifications that confer sensitivity to mTORC1 inhibitors remain unclear. Here, we demonstrate that loss of TSC2 in the E mu-myc murine lymphoma model leads to mTORC1 activation and accelerated oncogenesis caused by a defective apoptotic program despite compromised AKT phosphorylation. Tumors from Tsc2(+/-)E mu-Myc mice underwent rapid apoptosis upon blockade of mTORC1 by rapamycin. We identified myeloid cell leukemia sequence 1 (Mcl-1), a bcl-2 like family member, as a translationally regulated genetic determinant of mTORC1-dependent survival. Our results indicate that the extent by which rapamycin can modulate expression of Mcl-1 is an important feature of the rapamycin response.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18664580      PMCID: PMC2504845          DOI: 10.1073/pnas.0804821105

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  28 in total

1.  Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex.

Authors:  D D Sarbassov; David A Guertin; Siraj M Ali; David M Sabatini
Journal:  Science       Date:  2005-02-18       Impact factor: 47.728

2.  Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma.

Authors:  Francisco Vega; L Jeffrey Medeiros; Vasiliki Leventaki; Coralyn Atwell; Jeong Hee Cho-Vega; Ling Tian; Francois-Xavier Claret; George Z Rassidakis
Journal:  Cancer Res       Date:  2006-07-01       Impact factor: 12.701

3.  Gene expression-based chemical genomics identifies rapamycin as a modulator of MCL1 and glucocorticoid resistance.

Authors:  Guo Wei; David Twomey; Justin Lamb; Krysta Schlis; Jyoti Agarwal; Ronald W Stam; Joseph T Opferman; Stephen E Sallan; Monique L den Boer; Rob Pieters; Todd R Golub; Scott A Armstrong
Journal:  Cancer Cell       Date:  2006-09-28       Impact factor: 31.743

4.  Evasion of the p53 tumour surveillance network by tumour-derived MYC mutants.

Authors:  Michael T Hemann; Anka Bric; Julie Teruya-Feldstein; Andreas Herbst; Jonas A Nilsson; Carlos Cordon-Cardo; John L Cleveland; William P Tansey; Scott W Lowe
Journal:  Nature       Date:  2005-08-11       Impact factor: 49.962

5.  Determinants of sensitivity and resistance to rapamycin-chemotherapy drug combinations in vivo.

Authors:  Hans-Guido Wendel; Abba Malina; Zhen Zhao; Lars Zender; Scott C Kogan; Carlos Cordon-Cardo; Jerry Pelletier; Scott W Lowe
Journal:  Cancer Res       Date:  2006-08-01       Impact factor: 12.701

6.  Mcl-1 is overexpressed in multiple myeloma and associated with relapse and shorter survival.

Authors:  S Wuillème-Toumi; N Robillard; P Gomez; P Moreau; S Le Gouill; H Avet-Loiseau; J-L Harousseau; M Amiot; R Bataille
Journal:  Leukemia       Date:  2005-07       Impact factor: 11.528

7.  Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB.

Authors:  Dos D Sarbassov; Siraj M Ali; Shomit Sengupta; Joon-Ho Sheen; Peggy P Hsu; Alex F Bagley; Andrew L Markhard; David M Sabatini
Journal:  Mol Cell       Date:  2006-04-06       Impact factor: 17.970

8.  The mammalian target of rapamycin (mTOR) pathway regulates mitochondrial oxygen consumption and oxidative capacity.

Authors:  Stefan M Schieke; Darci Phillips; J Philip McCoy; Angel M Aponte; Rong-Fong Shen; Robert S Balaban; Toren Finkel
Journal:  J Biol Chem       Date:  2006-07-17       Impact factor: 5.157

9.  The c-myc oncogene driven by immunoglobulin enhancers induces lymphoid malignancy in transgenic mice.

Authors:  J M Adams; A W Harris; C A Pinkert; L M Corcoran; W S Alexander; S Cory; R D Palmiter; R L Brinster
Journal:  Nature       Date:  1985 Dec 12-18       Impact factor: 49.962

10.  mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt.

Authors:  Kathryn E O'Reilly; Fredi Rojo; Qing-Bai She; David Solit; Gordon B Mills; Debra Smith; Heidi Lane; Francesco Hofmann; Daniel J Hicklin; Dale L Ludwig; Jose Baselga; Neal Rosen
Journal:  Cancer Res       Date:  2006-02-01       Impact factor: 12.701

View more
  150 in total

1.  Synergistic activity of rapamycin and dexamethasone in vitro and in vivo in acute lymphoblastic leukemia via cell-cycle arrest and apoptosis.

Authors:  Chong Zhang; Yong-Ku Ryu; Taylor Z Chen; Connor P Hall; Daniel R Webster; Min H Kang
Journal:  Leuk Res       Date:  2011-12-03       Impact factor: 3.156

2.  Emerging therapeutics targeting mRNA translation.

Authors:  Abba Malina; John R Mills; Jerry Pelletier
Journal:  Cold Spring Harb Perspect Biol       Date:  2012-04-01       Impact factor: 10.005

3.  Selectively targeting Mcl-1 for the treatment of acute myelogenous leukemia and solid tumors.

Authors:  Gregory J Gores; Scott H Kaufmann
Journal:  Genes Dev       Date:  2012-02-15       Impact factor: 11.361

4.  MCL-1 is a stress sensor that regulates autophagy in a developmentally regulated manner.

Authors:  Marc Germain; Angela P Nguyen; J Nicole Le Grand; Nicole Arbour; Jacqueline L Vanderluit; David S Park; Joseph T Opferman; Ruth S Slack
Journal:  EMBO J       Date:  2010-12-07       Impact factor: 11.598

Review 5.  For better or for worse: the role of Pim oncogenes in tumorigenesis.

Authors:  Martijn C Nawijn; Andrej Alendar; Anton Berns
Journal:  Nat Rev Cancer       Date:  2010-12-09       Impact factor: 60.716

Review 6.  Attacking cancer's Achilles heel: antagonism of anti-apoptotic BCL-2 family members.

Authors:  Joseph T Opferman
Journal:  FEBS J       Date:  2015-09-15       Impact factor: 5.542

7.  Hypergrowth mTORC1 signals translationally activate the ARF tumor suppressor checkpoint.

Authors:  Alexander P Miceli; Anthony J Saporita; Jason D Weber
Journal:  Mol Cell Biol       Date:  2011-11-07       Impact factor: 4.272

8.  mTOR Complex 2 Stabilizes Mcl-1 Protein by Suppressing Its Glycogen Synthase Kinase 3-Dependent and SCF-FBXW7-Mediated Degradation.

Authors:  Junghui Koo; Ping Yue; Xingming Deng; Fadlo R Khuri; Shi-Yong Sun
Journal:  Mol Cell Biol       Date:  2015-04-27       Impact factor: 4.272

Review 9.  Common corruption of the mTOR signaling network in human tumors.

Authors:  S Menon; B D Manning
Journal:  Oncogene       Date:  2008-12       Impact factor: 9.867

10.  Cotargeting BCL-2 and PI3K Induces BAX-Dependent Mitochondrial Apoptosis in AML Cells.

Authors:  Mohamed Rahmani; Jewel Nkwocha; Elisa Hawkins; Xinyan Pei; Rebecca E Parker; Maciej Kmieciak; Joel D Leverson; Deepak Sampath; Andrea Ferreira-Gonzalez; Steven Grant
Journal:  Cancer Res       Date:  2018-03-20       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.